Federated Hermes, Inc. Graphite Bio, Inc. Transaction History

Federated Hermes, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$2.47 - $3.38 $4,458 - $6,100	-1,805 Reduced 0.44%	408,157 $1.06 Million
Q1 2023 May 08, 2023	SELL	$1.85 - $3.21 $1.2 Million - $2.08 Million	-648,539 Reduced 61.27%	409,962 $1 Million
Q4 2022 Feb 13, 2023	BUY	$2.82 - $3.59 $1,460 - $1,859	518 Added 0.05%	1,058,501 $3.51 Million
Q3 2022 Nov 14, 2022	BUY	$2.82 - $4.24 $4,723 - $7,102	1,675 Added 0.16%	1,057,983 $3.35 Million
Q3 2021 Nov 15, 2021	BUY	$15.81 - $28.39 $6.42 Million - $11.5 Million	406,308 Added 62.51%	1,056,308 $17.3 Million
Q2 2021 Aug 16, 2021	BUY	$18.5 - $30.73 $12 Million - $20 Million	650,000 New	650,000 $20 Million

637K

Ticker GRPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,211,200
Description
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.